Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (9) ·
(none, never marketed) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Fanapt (1) ·
Geodon (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Lunesta (1) ·
Mellaril (1) ·
Moban (1) ·
Mogadon (1) ·
Navane (1) ·
Nembutal (1) ·
Orap (1) ·
Placidyl (1) ·
Prolixin (1) ·
ProSom (1) ·
Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia) (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Saphris (1) ·
Seconal (1) ·
Sonata (1) ·
Stelazine (1) ·
THIP (1) ·
Thorazine (1) ·
Trilafon (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Melatonin receptor agonist (2) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Thioxanthene D2 antagonist (1)
uses:
starting dose:
preparations:
onset:
None (44) ·
Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (44) ·
6–10 h subjective; full pharmacologic effect considerably longer. (1) ·
Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.'"`UNIQ--ref-0000006D-QINU`"' (1)
halflife:
bioavailability:
None (44) ·
Not formally characterized in humans. (1) ·
Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.'"`UNIQ--ref-0000006F-QINU`"' (1)
pregnancy:
legal:
Showing below up to 46 results in range #1 to #46.